In addition to promoter CpG methylation, HOXA9 is regulated by miRNAs in NSCLC [26, 27], acute myeloid leukemia (AML) [63, 64], osteosarcoma [15], epithelial ovarian cancer [28], CRC [12], glioma [16, 65], and uveal melanoma [30]. Here, HOXA9 is linked to central nervous system cancer.